Buy, Sell or Hold: Novo-Nordisk (NVO-N) — Stock Predictions at Stockchase

skip to content

NYSE:NVO

107.74

1.14 (1.07%) 1d

Showing 1 to 15 of 96 entries

«
‹
1
2
3
4
5
›
»

Next Page

WEAK BUY

NVO vs. LLY Focused on weight loss and diabetes. One issue is the liquidity, as it doesn't work well for his covered call strategy. Still fairly expensive. LLY had great weight reduction results recently. LLY is at a discounted valuation, a more diversified business, and exposure to Alzheimer's. He prefers LLY, but you'd be OK on both.

biotechnology / pharmaceutical

PAST TOP PICK

(A Top Pick Feb 10/21, Up 46%) Believes company is leading insulin producer for diabetics. Revenues outside USA are increasing. Above average financial results from previous quarter was rewarded by market. Rising diabetes levels in society will be good for company. Company has very little debt and is looking at other products.

biotechnology / pharmaceutical

COMMENT

He was negative on this 5 years ago but now likes it and owns some for the long term. Insulin prices have normalized and it has a good weight loss drug. When asked to compare to Lilly he prefers NVO although Lilly is good too. The only concern is that this is a defensive growth stock and some might sell to buy cyclicals.

biotechnology / pharmaceutical

PAST TOP PICK

(A Top Pick Feb 10/21, Up 49%) Leading company for making insulin. The FDA approved their 2.5mg dose of weight-loss drug, which helped share prices. They are first to market with it. The expectations for earnings were moved higher. Getting more international sales in the long term. Stock is starting to get noticed by fund managers internationally.

biotechnology / pharmaceutical

BUY

A Danish drug company that makes insulin. He likes the pharma stocks, though have been underperforming. He owns many pharmas, but you can't own all of them.

biotechnology / pharmaceutical

HOLD

Largest producer of insulin in the world. Diabetes is one of the fastest-growing diseases. Will continue to do well.

biotechnology / pharmaceutical

TOP PICK

A long time favourite. Recent news was FDA approval of a diabetes drug that can also be used for weight-loss. (Analysts’ price target is $76.50)

biotechnology / pharmaceutical

TOP PICK

Take a pill once a week instead of injecting. Big implications moving forward. International sales have gone beyond what US sales were. Good entry point for the next 5-10 years. May get more diversified over time. No debt outstanding. Yield is 1.45% (Analysts’ price target is $75.73)

biotechnology / pharmaceutical

COMMENT

It's focused 90% in diabetes products which offers a competitive advantage. He owned this before, but sold it because its options liquidity is low in the US (he trades options). Instead, he owns its direct competitor, Eli Lily, which boasts more product diversity. (Both companies have phase 3 Covid drugs.) Novo is a leader in diabetes and good to own unless you trade options.

biotechnology / pharmaceutical

BUY

The largest maker of insulin in the world. They have a strong diabetes franchise. Type diabetes is growing incredibly quickly around the world. They are one of the few companies that are involved in Diabetes. He thinks it will continue to accelerate and why this one will do well. It is a great story at 21 times earnings and 2% dividend yield. He will continue to buy it.

biotechnology / pharmaceutical

BUY

If The Democrats Their goal is to sell outside the U.S. which they have done successfully, which have increased revenues, profits and dividends. Most importantly, their pill will replace people with type 2 diabetes from injecting insulin and helps people lose weight. They are the biggest insulin-maker in the world. This will be a big mover in coming years in pharma. You can take profits if the stock has moved up and is outsized in your portfolio.

biotechnology / pharmaceutical

PAST TOP PICK

(A Top Pick Sep 26/19, Up 29%) Diabetes and hemophilia. Diabetes continues to grow. NVO is at the sweet spot of that. Obesity will become a bigger and bigger issue.

biotechnology / pharmaceutical

PAST TOP PICK

(A Top Pick Aug 15/19, Up 38%) The biggest producer of insulin in the world. Type 2 diabetes is rapidly growing which helps NVO's growth. Very well-run. They have an obesity drug. A great demographic story. He continues to like it. He'd buy it here.

biotechnology / pharmaceutical

BUY on WEAKNESS

International sales were up 11% and US at 1% due to pricing issues there. They are picking up market shares which gives them pricing power and allows them to go into India and China to earn higher margins. Getting out of the US is important for them. Once you get a moat around their product, the oral insulin pill and weight loss, it's smooth sailing. He's owned this since 1995. There are periods they struggle but over time, it's a gift that keeps giving. With the number of diabetics growing around the world, they will have good demand for its products. Right now, he would pause but he would have it in your portfolio.

biotechnology / pharmaceutical

COMMENT

They have good exposure to the diabetes market, though less specialized growth in the next 10 years. They don't own it because their options are not liquid enough.

biotechnology / pharmaceutical

Showing 1 to 15 of 96 entries

«
‹
1
2
3
4
5
›
»

Next Page

Novo-Nordisk(NVO-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 4

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 5

Stockchase rating for Novo-Nordisk is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Novo-Nordisk(NVO-N) Frequently Asked Questions

What is Novo-Nordisk stock symbol?

Novo-Nordisk is a American stock, trading under the symbol NVO-N on the New York Stock Exchange (NVO). It is usually referred to as NYSE:NVO or NVO-N

Is Novo-Nordisk a buy or a sell?

In the last year, 5 stock analysts published opinions about NVO-N. 4 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Novo-Nordisk.

Is Novo-Nordisk a good investment or a top pick?

Novo-Nordisk was recommended as a Top Pick by on . Read the latest stock experts ratings for Novo-Nordisk.

Why is Novo-Nordisk stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Novo-Nordisk worth watching?

5 stock analysts on Stockchase covered Novo-Nordisk In the last year. It is a trending stock that is worth watching.

What is Novo-Nordisk stock price?

On 2022-05-27, Novo-Nordisk (NVO-N) stock closed at a price of $107.74.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

© Stockchase Inc.